Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis

References

• WynnTACommon and unique mechanisms regulate fibrosis in various fibroproliferative diseasesJ Clin Invest2007117352452917332879
   PubMed Web of Science ®Google Scholar
• AkhmetshinaAPalumboKDeesCActivation of canonical Wnt signalling is required for TGF-β-mediated fibrosisNat Commun2012373522415826
   PubMed Web of Science ®Google Scholar
• GabrielliAAvvedimentoEVKriegTSclerodermaN Engl J Med2009360191989200319420368
   PubMed Web of Science ®Google Scholar
• ZahrAASalamaMECarreauNBone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategiesHaematologica2016101666067127252511
   PubMed Web of Science ®Google Scholar
• ThieleJRompcikVWagnerSFischerRVascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: an immunomorphometric study on trephine biopsies of the bone marrowBr J Haematol19928022272341550781
   PubMed Web of Science ®Google Scholar
• AgarwalAMorroneKBartensteinMZhaoZJVermaAGoelSBone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-βStem Cell Investig201635
   PubMedGoogle Scholar
• BaxterEJScottLMCampbellPJAcquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersLancet200536594641054106115781101
   PubMed Web of Science ®Google Scholar
• KralovicsRPassamontiFBuserASA gain-of-function mutation of JAK2 in myeloproliferative disordersN Engl J Med2005352171779179015858187
   PubMed Web of Science ®Google Scholar
• LevineRLWadleighMCoolsJActivating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell20057438739715837627
   PubMed Web of Science ®Google Scholar
• Jakafi [package insert]Wilmington (DE)Incyte Corporation2016
   Google Scholar
• VerstovsekSKantarjianHMesaRASafety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosisN Engl J Med2010363121117112720843246
   PubMed Web of Science ®Google Scholar
• HarrisonCKiladjianJJAl-AliHKJAK inhibition with ruxolitinib versus best available therapy for myelofibrosisN Engl J Med2012366978779822375970
   PubMed Web of Science ®Google Scholar
• VerstovsekSMesaRAGotlibJA double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisN Engl J Med2012366979980722375971
   PubMed Web of Science ®Google Scholar
• HarrisonCNVannucchiAMKiladjianJJLong-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisLeukemia20163081701170727211272
   PubMed Web of Science ®Google Scholar
• VerstovsekSMesaRAGotlibJLong-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialJ Hematol Oncol20171015528228106
   PubMed Web of Science ®Google Scholar
• HartSGohKCNovotny-DiermayrVSB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignanciesLeukemia201125111751175921691275
   PubMed Web of Science ®Google Scholar
• HatzimichaelETsolasEBriasoulisEProfile of pacritinib and its potential in the treatment of hematologic disordersJ Blood Med2014514315225170285
   PubMedGoogle Scholar
• SingerJWAl-FayoumiSMaHKomrokjiRSMesaRVerstovsekSComprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitorJ Exp Pharmacol20168111927574472
   PubMedGoogle Scholar
• KomrokjiRSSeymourJFRobertsAWResults of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosisBlood2015125172649265525762180
   PubMed Web of Science ®Google Scholar
• MascarenhasJHoffmanRTalpazMResults of the PERSIST-2 phase 3 study of pacritinib (Pac) versus best available therapy (BAT), including ruxolitinib (Rux), in patients (pts) with myelofibrosis (MF) and platelet counts<100,000/μLBlood201612822LBA5
   Web of Science ®Google Scholar
• MesaRAEgyedMSzokeASuvorovAPerkinsAMayerJPacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60-week follow-up of the phase III PERSIST-1 trialJ Clin Oncol20163415 Suppl7065
   Web of Science ®Google Scholar
• VerstovsekSOdenikeOSingerJWGranstonTAl-FayoumiSDeegHJPhase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignanciesJ Hematol Oncol2016913727931243
   PubMed Web of Science ®Google Scholar
• MesaRAVannucchiAMMeadAPacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialLancet Haematol201745e225e23628336242
   PubMed Web of Science ®Google Scholar
• Al-FayoumiSWatsonRO’MahonyASingerJWComparative biomarker profiles of pacritinib, momelotinib, pexidartinib, and ruxolitinib using BioMAP Diversity Plus PanelEur J Cancer201669Suppl 1S136
   Web of Science ®Google Scholar
• HunterCAJonesSAIL-6 as a keystone cytokine in health and diseaseNat Immunol201516544845725898198
   PubMed Web of Science ®Google Scholar
• WynnTARamalingamTRMechanisms of fibrosis: therapeutic translation for fibrotic diseaseNat Med20121871028104022772564
   PubMed Web of Science ®Google Scholar
• RousselLHouleFChanCIL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammationJ Immunol201018484531453720228195
   PubMed Web of Science ®Google Scholar
• JovanovicDVDi BattistaJAMartel-PelletierJIL-17 stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α, by human macrophagesJ Immunol19981607351335219531313
   PubMed Web of Science ®Google Scholar
• BatallerRBrennerDALiver fibrosisJ Clin Invest2005115220921815690074
   PubMed Web of Science ®Google Scholar
• EkstedtMFranzenLEMathiesenULLong-term follow-up of patients with NAFLD and elevated liver enzymesHepatology200644486587317006923
   PubMed Web of Science ®Google Scholar
• YounossiZMKoenigABAbdelatifDFazelYHenryLWymerMGlobal epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomesHepatology2016641738426707365
   PubMed Web of Science ®Google Scholar
• EllisELMannDAClinical evidence for the regression of liver fibrosisJ Hepatol20125651171118022245903
   PubMed Web of Science ®Google Scholar
• YanguasSCCogliatiBWillebrordsJExperimental models of liver fibrosisArch Toxicol20169051025104826047667
   PubMed Web of Science ®Google Scholar
• IredaleJPModels of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organJ Clin Invest2007117353954817332881
   PubMed Web of Science ®Google Scholar
• LiedtkeCLueddeTSauerbruchTExperimental liver fibrosis research: update on animal models, legal issues and translational aspectsFibrogenesis Tissue Repair2013611924274743
   PubMedGoogle Scholar
• WynnTAFibrotic disease and the T(H)1/T(H)2 paradigmNat Rev Immunol20044858359415286725
   PubMed Web of Science ®Google Scholar
• FujiiMShibazakiYWakamatsuKA murine model for nonalcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinomaMed Mol Morphol201346314115223430399
   PubMed Web of Science ®Google Scholar
• OhnoYAnimal experiments recommended by the Japanese Pharmacological Society (evaluation and decrease of pain): introduction and new guidelines for animal experiments for the Japanese Pharmacological SocietyNihon Yakurigaku Zasshi2007129159 Japanese17220569
   PubMedGoogle Scholar
• KleinerDEBruntEMvan NattaMDesign and validation of a histological scoring system for nonalcoholic fatty liver diseaseHepatology20054161313132115915461
   PubMed Web of Science ®Google Scholar
• GranzowMSchierwagenRKleinSAngiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosisHepatology201460133434824619965
   PubMed Web of Science ®Google Scholar
• WeberAWasiliewPKrachtMInterleukin-1 (IL-1) pathwaySci Signal20103105cm120086235
   PubMed Web of Science ®Google Scholar
• YeZHGaoLWenDYHeYPangYYChenGDiagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlasOnco Targets Ther2017101711172328356759
   PubMed Web of Science ®Google Scholar
• ChenYZengZShenXWuZDongYChengJCMicroRNA-146a-5p negatively regulates pro-Inflammatory cytokine secretion and cell activation in lipopolysaccharide stimulated human hepatic stellate cells through inhibition of Toll-like receptor 4 signaling pathwaysInt J Mol Sci2016177E107627399683
   PubMed Web of Science ®Google Scholar
• AhmadRShihabPKThomasRIncreased expression of the interleukin-1 receptor-associated kinase (IRAK)-1 is associated with adipose tissue inflammatory state in obesityDiabetol Metab Syndr201577126312071
   PubMed Web of Science ®Google Scholar
• LeeJYHwangDHThe modulation of inflammatory gene expression by lipids: mediation through Toll-like receptorsMol Cells200621217418516682810
   PubMed Web of Science ®Google Scholar
• MaitraUDavisSReillyCMLiLDifferential regulation of Foxp3 and IL-17 expression in CD4 T helper cells by IRAK-1J Immunol200918295763576919380824
   PubMed Web of Science ®Google Scholar
• MederackeIHsuCCTroegerJSFate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiologyNat Commun20134282324264436
   PubMed Web of Science ®Google Scholar
• TanZQianXJiangRIL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activationJ Immunol201319141835184423842754
   PubMed Web of Science ®Google Scholar
• PixleyFJStanleyERCSF-1 regulation of the wandering macrophage: complexity in actionTrends Cell Biol2004141162863815519852
   PubMed Web of Science ®Google Scholar
• PradereJPKluweJde MinicisSHepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in miceHepatology20135841461147323553591
   PubMed Web of Science ®Google Scholar
• WynnTAVannellaKMMacrophages in tissue repair, regeneration, and fibrosisImmunity201644345046226982353
   PubMed Web of Science ®Google Scholar
• VerstovsekSMesaRAFoltzLMPRM-151 in myelofibrosis: durable efficacy and safety at 72 weeksBlood20151262356
   Web of Science ®Google Scholar
• NakagamiHKiomy OsakoMNakagamiFPrevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartanInt J Mol Med201026447748120818485
   PubMed Web of Science ®Google Scholar
• TamakiYNakadeYYamauchiTAngiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitisJ Gastroenterol201348449150322886508
   PubMed Web of Science ®Google Scholar
• HaliciZBilenHAlbayrakFDoes telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes?Eur J Pharmacol20096141–314615219406119
   PubMed Web of Science ®Google Scholar
• JinHYamamotoNUchidaKTeraiSSakaidaITelmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined dietBiochem Biophys Res Commun2007364480180717963695
   PubMed Web of Science ®Google Scholar
• AlamSKabirJMustafaGGuptaUHasanSKAlamAKEffect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: a 1-year randomized control trialSaudi J Gastroenterol2016221697626831610
   PubMed Web of Science ®Google Scholar
• BensonSCPershadsinghHAHoCIIdentification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activityHypertension2004435993100215007034
   PubMed Web of Science ®Google Scholar
• MandeliaCCollyerEMansoorSPlasma cytokeratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver diseaseJ Pediatr Gastroenterol Nutr201663218118726835904
   PubMed Web of Science ®Google Scholar
• FeldsteinAEWieckowskaALopezARLiuYCZeinNNMcCulloughAJCytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation studyHepatology20095041072107819585618
   PubMed Web of Science ®Google Scholar